<DOC>
	<DOCNO>NCT02279485</DOCNO>
	<brief_summary>This open-label , 2-arm , single-dose , randomize crossover study . The study enroll total 100 subject ( 2 arm 50 subject arm ) . In Arm 1 , bioequivalence oral suspension tablet formulation perampanel evaluate fasted condition ; Arm 2 , bioequivalence oral suspension tablet formulation evaluate fed condition . In study arm , subject randomize Study Day 1 Treatment Period 1 receive single 12-mg dose perampanel either oral suspension tablet , receive alternative treatment Study Day 43 Treatment Period 2 . Drug administration separate washout least 6 week two treatment period .</brief_summary>
	<brief_title>A Study Demonstrate Bioequivalence Between 12-mg Dose Oral Suspension Formulation Perampanel 12-mg Tablet Formulation Perampanel Under Fasted Fed Conditions Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Healthy male female , age 18 55 year , inclusive , time informed consent . 2 . Body mass index ( BMI ) 18 32 kg/m2 , inclusive Screening . 3 . Females must lactate pregnant Screening Baseline . 4 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( eg , total abstinence , doublebarrier method [ condom plus diaphragm spermicide ] , vasectomize partner confirm azoospermia , intrauterine device , contraceptive implant , oral contraceptive contain levogesterol ) throughout entire study period 30 day study drug discontinuation . Females use hormonal contraceptive contain levogesterol must another form contraception ( double barrier method . ) well . If currently abstinent , subject must agree use doublebarrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 30 day study drug discontinuation . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e . bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . Exclusion Criteria 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical attention within 4 week dose . 2 . Evidence disease may influence outcome study within 4 week dose , eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism . 3 . Any history gastrointestinal surgery may affect PK profile perampanel , eg , hepatectomy , nephrotomy , cholecystectomy , digestive organ resection gastrointestinal procedure purpose weight loss ( include Lapband ) , would slow gastric empty . 4 . Any clinically abnormal symptom organ impairment find medical history Screening , physical examination , vital sign , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment Screening Baseline . 5 . Any laboratory abnormality consider clinically significant investigator . 6 . A prolonged QT/QTc interval ( QTc great 450 msec ) demonstrate upon repeat ECG Screening Baseline . 7 . History prolong QT/QTc interval . 8 . History risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT syndrome ) . 9 . History ischemic heart disease ( eg , acute coronary syndrome , stable angina ) , syncope cardiac arrhythmia . 10 . Siting heart rate le 40 great 100 beats/min Screening Baseline Period 1 sit systolic blood pressure great 140 mmHg less 90 mmHg diastolic blood pressure great 90 mmHg less 60 mmHg Screening Baseline . 11 . Hemoglobin le 11.5 g/dLfor female less 12.5 g/dL male screen Baseline checkin Period 1 . 12 . Subjects experience weight loss gain great 10 % Screening dosing . 13 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within 1 week dosing . 14 . Hypersensitivity study drug excipients . 15 . Known history food allergy presently experience significant seasonal perennial allergy Screening . 16 . Known human immunodeficiency virus ( HIV ) positive Screening . 17 . Active viral hepatitis ( B C ) demonstrate positive serology Screening . 18 . History use illegal ( legalize ) recreational drug past year . 19 . History drug alcohol dependency abuse within approximately last 2 year positive urine drug test breath alcohol test Screening Baseline . 20 . Engagement strenuous exercise within 2 week dose ( eg , marathon runner , weight lifter ) . 21 . Currently enrol another clinical trial use investigational drug device within 30 day precede informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fasted</keyword>
	<keyword>Fed</keyword>
</DOC>